FDA Peptide Tracker

Survodutide: live FDA regulatory status

GLP-1/glucagon · MASH · Investigational

The two signals

Plain-English verdict: amber.

Regulatory status: Investigational (Phase 3).

These two never collapse into one. Removal from a list is not the same as legal-to-compound, and neither is the same as available.

Availability at Peptós.LIFE

Education only

What happens next

SYNCHRONIZE Phase-3 (projected) — 2026–2027

Regulatory timeline

Survodutide: common questions

Is Survodutide available in 2026?
No. Survodutide is investigational — it is in clinical trials and has not been approved by the FDA for any use. There is no legal route to a prescription outside a trial.
Can I get Survodutide right now?
No. Survodutide is education-only at Peptós.LIFE. Anything sold as Survodutide today is not a regulated medicine.
Is Survodutide the same as a compounded peptide?
No, and conflating them is a common error. Survodutide is an investigational drug in a manufacturer's trial programme. Compounded peptides are prepared by a pharmacy for an individual patient under 503A. Different pathways, different rules.
What happens next for Survodutide?
SYNCHRONIZE Phase-3 (projected), 2026–2027. Trial readouts are not approvals, and approval would be the manufacturer's, not ours.

PCAC is advisory: its Jul 2026 recommendation leads to rulemaking, not instant availability. A favorable advisory vote is a recommendation, not FDA approval or authorization to compound. Realistic earliest legitimate access is late 2026 into 2027. Reclassification is not the same as FDA approval. Compounded medications are not evaluated or approved by the FDA for safety, efficacy, or quality, where that applies, we say so, plainly.

Primary source: FDA source record

See the full status board or this molecule's knowledge-base monograph.

Embed this card on your site · free, CC BY 4.0, no key.

Last updated July 26, 2026 · Peptós.LIFE · Not medical advice.